04:20 , Dec 21, 2018 |  BC Innovations  |  Product R&D

Cell therapies seek solid ground

To make cell therapies work in solid tumors, drug companies will have to either master combination therapies or figure out how to make their treatments trigger broad immune responses that extend beyond the antigen specificity...
07:00 , Oct 25, 2012 |  BC Innovations  |  Cover Story

Melanoma's hidden act

Researchers at the University of Bonn and the Johannes Gutenberg University Mainz have shown that melanoma cells can acquire resistance to adoptive T cell transfer therapies by dedifferentiating themselves to hide antigens. 1 The group...
08:00 , Feb 11, 2010 |  BC Innovations  |  Tools & Techniques

Synthetic saponins

Memorial Sloan-Kettering Cancer Center researchers have designed vaccine adjuvants that are synthetic derivatives of Antigenics Inc. 's QS-21, 1 a purified fraction of a plant extract containing a mixture of two natural saponin isomers. The...
07:00 , Apr 15, 2003 |  BC Extra  |  Clinical News

CancerVax resumes Phase III enrollment

CancerVax (Carlsbad, Calif.) said the FDA released a partial clinical hold on enrollment in the company's international Phase III trials of Canvaxin for post-surgical treatment of patients with stage III or IV melanoma. In May...
08:00 , Feb 3, 2003 |  BC Week In Review  |  Clinical News

Canvaxin regulatory update

The FDA granted Fast Track designation to CancerVax's Canvaxin vaccine for the post-surgical treatment of metastatic melanoma. Canvaxin is in two Phase III trials in patients with Stage III or IV melanoma. The trials are...
08:00 , Jan 13, 2003 |  BC Week In Review  |  Clinical News

Canvaxin: Phase II data; 2 Phase III trials on hold

Researchers published in the Journal of Clinical Oncology a previously reported U.S. Phase II study of Canvaxin in 263 patients who had undergone complete resection of clinically detectable Stage IV melanoma showed the median overall...
08:00 , Dec 16, 2002 |  BC Week In Review  |  Clinical News

Canvaxin: Phase II data; 2 Phase III trials on hold

In a U.S. Phase II trial in 2,602 patients that underwent lympadenectomy to treat Stage III melanoma, a retrospective matched-pair analysis showed the median overall survival between Canvaxin-treated patients and non-treated patients was 55.3 months...
07:00 , Sep 5, 1995 |  BC Week In Review  |  Clinical News

Melanoma vaccine data

Researchers at the John Wayne Cancer Institute (Santa Monica, Calif.) reported a retrospective analysis over 22 years of 984 patients treated for melanoma metastasized to the lung or chest, of which 106 were treated with...